Balincan USA, Inc.
BCNN · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.01 | 0.01 |
| FCF Yield | 0.00% | -121.84% | -39.03% | -30.46% |
| EV / EBITDA | 0.00 | -3,670.40 | -17.09 | -6.34 |
| Quality | ||||
| ROIC | 0.00% | 0.02% | 5.80% | 11.21% |
| Gross Margin | 36.23% | 42.55% | 54.06% | 9.97% |
| Cash Conversion Ratio | 0.15 | -0.29 | -0.08 | 0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | 254.17% | 728.28% | 862.21% | 1,124,229.28% |
| Free Cash Flow Growth | 0.00% | -58.27% | -16.18% | -1,745.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -3,225.54 | -12.83 | -4.37 |
| Interest Coverage | 0.24 | -0.00 | -1.36 | -2.31 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -391.10 | -1,131.86 | -879.61 |